Inventor · disambiguated record
Wenjun Ouyang
Also filed as: OUYANG WENJUN
15 granted patents·27 pending applications·86 citations·filing 2004–2022
92Inventor score
Top patents by PatentIndex Score
42 records- 0195US9815880B2IL-22 Fc fusion proteinsGENENTECH INC·Filed 2016·Granted Nov 14, 2017·15 cites·18 claims
- 0291US10160793B2Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteinsGENENTECH INC·Filed 2014·Granted Dec 25, 2018·9 cites·30 claims
- 0391US7479544B2Anti-PRO87299 antibodiesGENENTECH INC·Filed 2004·Granted Jan 20, 2009·33 cites·18 claims
- 0490US10087227B2Nucleic acids encoding IL-22 Fc fusion proteinsGENENTECH INC·Filed 2016·Granted Oct 2, 2018·5 cites·26 claims
- 0588US7737259B2Compositions and methods for the treatment of diseases and disorders associated with cytokine signalingGENENTECH INC·Filed 2006·Granted Jun 15, 2010·14 cites·25 claims
- 0683US7863422B2Anti-PRO87299 antibodiesGENENTECH INC·Filed 2008·Granted Jan 4, 2011·4 cites·12 claims
- 0781US11155591B2Methods of treating acute pancreatitis using IL-22 fc fusion proteinsGENENTECH INC·Filed 2018·Granted Oct 26, 2021·1 cites·27 claims
- 0879US8790642B2Cross-reactive and bispecific anti-IL-17A/F antibodiesCHEN YONGMEI·Filed 2009·Granted Jul 29, 2014·5 cites·11 claims
- 0978US2023063741A1IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USEGENENTECH INC·Filed 2022·Application pending·0 cites
- 1071US11332507B2IL-22 Fc fusion proteinsGENENTECH INC·Filed 2018·Granted May 17, 2022·0 cites·13 claims
- 1171US11130791B2Methods for treating metabolic syndrome using IL-22 Fc fusion proteinsGENENTECH INC·Filed 2018·Granted Sep 28, 2021·0 cites·29 claims
- 1271US2020377585A1Il-17a/f heterologous polypeptides and therapeutic uses thereofNOVARTIS PHARMA AG·Filed 2020·Application pending·0 cites
- 1369US11136365B2Methods for preventing or treating cardiovascular conditions using il-22 fc fusion proteinsGENENTECH INC·Filed 2018·Granted Oct 5, 2021·0 cites·28 claims
- 1469US2010034817A1Compositions and methods for the treatment of immune related diseasesGENENTECH INC·Filed 2009·Application pending·0 cites
- 1566US2009081229A1Anti-pro87299 antibodiesGENENTECH INC·Filed 2008·Application pending·0 cites
- 1666US2021338778A1Methods for treatment of microbial disordersGENENTECH INC·Filed 2021·Application pending·0 cites
- 1766US2014371086A1Compositions and methods for the treatment of immune related diseasesGENENTECH INC·Filed 2014·Application pending·0 cites
- 1865US10584155B2Pharmaceutical compositions of IL-22 Fc fusion proteinsGENENTECH INC·Filed 2017·Granted Mar 10, 2020·0 cites·29 claims
- 1964US10544198B2Methods of accelerating or improving wound healing using IL-22 FC fusion proteinsGENENTECH INC·Filed 2017·Granted Jan 28, 2020·0 cites·40 claims
- 2064US2015166631A1Anti-pro87299 antibodiesGENENTECH INC·Filed 2014·Application pending·0 cites
- 2161US2009202475A1Compositions and methods for treatment of microbial disordersGENENTECH INC·Filed 2008·Application pending·0 cites
- 2260US2007184444A1Compositions and methods for the treatment of immune related diseasesABBAS ALEXANDER·Filed 2004·Application pending·0 cites
- 2358US2012171208A1Anti-PRO87299 AntibodiesCLARK HILARY·Filed 2012·Application pending·0 cites
- 2457US2013165332A1Compositions and methods for the treatment of immune related diseasesABBAS ALEXANDER·Filed 2012·Application pending·0 cites
- 2557US2023040604A1Interleukin-2 in combination with tnf receptor family members for the expansion of t-regulatory cellsAMGEN INC·Filed 2020·Application pending·0 cites
- 2655US9512217B2Antibodies binding to IL-17AGENENTECH INC·Filed 2014·Granted Dec 6, 2016·0 cites·8 claims
- 2755US2007160576A1IL-17A/F heterologous polypeptides and therapeutic uses thereofGENENTECH INC·Filed 2006·Application pending·0 cites
- 2854US2022204606A1Il-17a/f heterologous polypeptides and therapeutic uses thereofNOVARTIS PHARMA AG·Filed 2021·Application pending·0 cites
- 2952US2011245090A1Compositions and methods for the treatment of immune related diseasesABBAS ALEXANDER·Filed 2011·Application pending·0 cites
- 3051US9555107B2Compositions and methods for the treatment of diseases and disorders associated with cytokine signalingCHEN YVONNE M·Filed 2012·Granted Jan 31, 2017·0 cites·2 claims
- 3151US2013052159A1Methods for treatment of microbial disordersABBAS ALEXANDER R·Filed 2012·Application pending·0 cites
- 3249US2018355009A1IL-22 Fc FUSION PROTEIN AND METHODS OF USEGENENTECH INC·Filed 2018·Application pending·0 cites
- 3349US2017291940A1Il-17a/f heterologous polypeptides and therapeutic uses thereofGENENTECH INC·Filed 2016·Application pending·0 cites
- 3448US2011280828A1Methods for treatment of microbial disordersABBAS ALEXANDER R·Filed 2011·Application pending·0 cites
- 3546US2021301020A1Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitorsAMGEN INC·Filed 2019·Application pending·0 cites
- 3645US2009175855A1Novel compositions and methods for the treatment of immune related diseasesCLARK HILARY·Filed 2007·Application pending·0 cites
- 3743US2010316596A1Compositions and methods for treatment of diseases and disorders associated with cytokine signalingCHEN YVONNE M·Filed 2010·Application pending·0 cites
- 3841US2013302347A1Novel receptor-ligand interaction and uses thereofGENENTECH INC·Filed 2013·Application pending·0 cites
- 3939US2011256126A1IL-17A/F Heterologous Polypeptides and Therapeutic Uses ThereofARNOTT DAVID P·Filed 2011·Application pending·0 cites
- 4039US2012174239A1Novel PRO1199 gene disruptions, and methods relating theretoANDERSON STEPHEN JAY·Filed 2011·Application pending·0 cites
- 4132US2010266595A1Treatment of insulin-resistant disordersKOLUMAM GANESH A·Filed 2010·Application pending·0 cites
- 4230US2012201821A1Treatment of Gastrointestinal Inflammation and Psoriasis and AsthmaGONZALEZ JR LINO·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Wenjun Ouyang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →